Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings is organized by Physicians' Education Resource, LLC (PER).
Release Date: February 28, 2023
Expiration Date: February 28, 2024.
Description:
This online, on-demand virtual symposium brings together renowned experts in metastatic castrate-sensitive prostate cancer (mCSPC) and castrate-resistant prostate cancer (mCRPC). In this educational program, these experts discuss unmet clinical needs in CSPC and CRPC, mechanisms of action of CDK4/6 inhibitors, and recent clinical trial data with these agents to inform physicians on practice-changing evidence to optimize care and survival outcomes for their patients.
This educational activity is an archive of the live satellite symposium held on February 17, 2023.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
- Explain the pathophysiological mechanisms of CDK4/6 dysregulation in prostate cancer and rationale underlying their inhibition in advanced CSPC and CRPC
- Assess study design and clinical updates on CDK4/6 inhibitors investigated for the treatment of patients with advanced CSPC and CRPC
- Evaluate evidence from pivotal trials on CDK4/6 inhibitors within the context of evolving therapeutic strategies for patients with advanced prostate cancer
- Develop proactive strategies to monitor and mitigate adverse events associated with CDK4/6 inhibitors evaluated in patients with prostate cancer